The metabolic syndrome and nonalcoholic fatty liver disease

Panminerva Medica

Volumn 48, Issue 1, 2006, Pages 41-48

  Collantes, R S ^a   Ong, J P ^a   Younossi, Z M ^a  

^a INOVA FAIRFAX HOSPITAL   (United States)

Author keywords

Fatty liver; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ANTIDIABETIC AGENT;

FATTY LIVER; HUMAN; INSULIN RESISTANCE; METABOLIC SYNDROME X; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; RISK FACTOR; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FATTY LIVER; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS; WEIGHT LOSS;

EID: 33745046881     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
2. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:111-6.
3. Weston SR, Leyden W, Murphy R, Bass NM, Bell BP, Manos MM et al. Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease. Hepatology 2005;41:372-9.
4. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-9.
5. Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ 2005;172:899-905.
6. Younossi ZM, Diehl AM, Ong JP. nonalcoholic fatty liver disease: and agenda for clinical research. Hepatology 2002;35:746-52.
7. McCullough AJ. Update on nonalcoholic fatty liver disease. J Clin Gastroenterol 2002;34:255-62.
8. Saglam K, Kilic R, Yilmaz MI, Gulec M, Baykal Y, Kutlu M. Insulin resistance in patients with steatohepatitis. Hepatogastroenterology 2003;50:456-9.
9. Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss. Diabetes Metab 2000;26:98-106.
10. Comert B, Mas MR, Erdem H, Dinc A, Saglamkaya U, Cigerim M et al. Insulin resistance in non-alcoholic steatohepatitis. Dig Liver Dis 2001;33:353-8.
11. Knobler H, Schattner A, Zhornicki T, Malnick SD, Keter D, Sokolovskaya N et al. Fatty liver: an additional and treatable feature of the insulin resistance syndrome. QJM 1999;92:73-9.
12. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50.
13. Ong J, Younossi ZM. Approach to the diagnosis and treatment of non-alcoholic fatty liver disease. Clin Liver Dis 2005;9:617-34.
14. Choudhury J, Sanyal AJ. Insulin resistance and the pathogenesis of non-alcoholic fatty liver disease. Clin Liver Dis 2004;8:575-94, ix.
15. National Institutes of Health - National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program Expert Panel (NCEP) on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). Final Report, 2001.
16. Rao G. Insulin resistance syndrome. Am Fam Physician 2001;63:1159-63, 1165-6.
17. Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004;33:283-303.
18. National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH-NHLBI, 1998, NIH Publication No. 98-4083. Bethesda, MD, USA.
19. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003;37:917-23.
20. Erratum in: Hepatology 2003;38:536.
21. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol 2004;2:262-5.
22. Erratum in: Clin Gastroenterol Hepatol 2004;2:522.
23. Ong JP, Elariny H, Collantes R, Younoszai A, Chandhoke V, Reines HD et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg 2005;15:310-5.
24. Sjostrom L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B et al.; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-93.
25. Mulhall BP, Younossi ZM. Nonalcoholic steatohepatitis. Curr Treat Options Gastroenterol 2004;7:423-30.
26. Mofrad P, Contos MJ, Haque M, Sargeant C, Fisher RA, Luketic VA et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-92.
27. Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004;164:2169-75.
28. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50.
29. Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod Pathol 1998;11:560-5.
30. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-74.
31. Gramlich T, Kleiner DE, McCullough AJ, Matteoni CA, Boparai N, Younossi ZM. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol 2004;35:196-9.
32. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
33. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.
34. Ford ES. Prevalence of the metabolic syndrome in US populations. Endocrinol Metab Clin North Am 2004;33:333-50.
35. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004;33:351-75, table of contents.
36. World Health Organization. Global Strategy for Diet, Physical Activity, and Health, http://www.who.int/dietphysicalactivity/publications/facts/ obesity/en/print.html
37. Department of Health and Human Services - Centers for Disease Control and Prevention. Overweight and Obesity: Obesity Trends. http://www.cdc.gov/nccdphp/ dnpa/obesity/trend/maps/index.htm
38. World Health Organization. Diabetes mellitus. Fact sheet No138. Revised April 2002. http://www.who.int/mediacentre/factsheets/fs138/ en/print.html
39. National Center for Chronic Disease Prevention and Health Promotion - Center for Disease Control. National Diabetes Surveillance System - Prevalence of Diabetes. http://www.cdc.gov/diabetes/statistics/prev/ national/figage.htm
40. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004;27:2057-66.
41. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946-56.
42. Grundy SM. What is the contribution of obesity to the metabolic syndrome? Endocrinol Metab Clin North Am 2004;33:267-82, table of contents.
43. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40.
44. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
45. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
46. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004;126:586-97.
47. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-71.
48. Younossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, Tavill A et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 2004;38:705-9.
49. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis 2001;21:27-41.
50. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29.
51. Ukkola O, Santaniemi M. Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 2002;80:696-702.
52. Kaplan LM. Leptin, obesity, and liver disease. Gastroenterology 1998;115:997-1001.
53. Kowdley KV, Pratt DS. Adiponectin: tipping the scales from NAFLD to NASH? Gastroenterology 2005;128:511-3; author reply 513.
54. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-52.
55. Graham DJ, Drinkard CR, Shatin D. Incidence of idiopathic acute liver failure and hospitalized liver injury in patients treated with troglitazone. Am J Gastroenterol 2003;98:175-9.
56. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, DeFronzo RA. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2004;89:4312-9.
57. Karlsson HK, Hallsten K, Bjornholm M, Tsuchida H, Chibalin AV, Virtanen KA et al. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Diabetes 2005;54:1459-67.
58. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-26.
59. Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96.
60. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-g ligand rosiglitazone. Hepatology 2003;38:1008-17.
61. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996;23:1464-7.
62. Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004;39:770-8.
63. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58.
64. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.